1991
DOI: 10.1159/000186665
|View full text |Cite
|
Sign up to set email alerts
|

Decreased Albuminuria by Pravastatin in Hyperlipidemic Diabetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0
1

Year Published

1994
1994
2012
2012

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 32 publications
(13 citation statements)
references
References 9 publications
0
12
0
1
Order By: Relevance
“…Whether these abnormalities are a cause, a consequence or an epiphenomenon of dia betic nephropathy is at present unknown. Interestingly, two recent reports from Japan described a reduction in albu minuria of diabetic patients after 2 months of therapy with pravastatin [32,33], a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. In another uncontrolled study, Rabelink et al [34] reported a partial remission of the nephrotic syndrome in 7 patients treated with simvastatin (another HMG-CoA reductase inhibitor) for 48 weeks.…”
Section: Clinical Evidencementioning
confidence: 99%
“…Whether these abnormalities are a cause, a consequence or an epiphenomenon of dia betic nephropathy is at present unknown. Interestingly, two recent reports from Japan described a reduction in albu minuria of diabetic patients after 2 months of therapy with pravastatin [32,33], a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. In another uncontrolled study, Rabelink et al [34] reported a partial remission of the nephrotic syndrome in 7 patients treated with simvastatin (another HMG-CoA reductase inhibitor) for 48 weeks.…”
Section: Clinical Evidencementioning
confidence: 99%
“…In patients with type II diabetes the current data are less clear, with some studies showing a correlation between plasma lipids and progression of diabetic nephropathy [17, 18]while others could not find an association between hyperlipidemia and diabetic nephropathy [19, 20]. A few studies with lipid-lowering agents report beneficial effects of these drugs on diabetic nephropathy with decrease in proteinuria and slowing of the decline in glomerular filtration rate (GFR) [21, 22, 23]. However, the mechanism by which hyperglycemia and hyperlipidemia exert their harmful effect on the kidney remains largely unknown, and animal models suitable for the investigation of diabetic nephropathy have major limitations.…”
Section: Introductionmentioning
confidence: 99%
“…The first is that the increased serum lipoprotein lev els may precede and possibly cause microalbuminuria. In agreement with the notion that lipids may be involved in glomerulosclerosis and the progression of renal disease [52], cholesterol-fed hypertensive renovascular rats were more albuminuric than their hypertensive controls [53], However, hyperlipidemia and increased UAE were disso ciated in subjects with primary' hypercholesterolemia [54] and aggressive pharmacological cholesterol lowering had unpredictable effects on UAE in diabetics [55,56], The alternative is that microalbuminuria may actually pre cede and cause dyslipidemia. This important possibility was, to some extent, substantiated in type 2 diabetics [57], but no studies have been performed in hypertensive patients.…”
Section: Total Cholesterolmentioning
confidence: 53%